New: Introducing the Finviz Crypto Map

Learn More
Last Close
Aug 15 04:00PM ET
8.04
Dollar change
+0.14
Percentage change
1.77
%
IndexRUT P/E- EPS (ttm)-11.42 Insider Own0.49% Shs Outstand90.80M Perf Week22.19%
Market Cap730.03M Forward P/E9.78 EPS next Y0.82 Insider Trans12.38% Shs Float90.36M Perf Month62.42%
Enterprise Value1.89B PEG- EPS next Q0.15 Inst Own110.85% Short Float14.33% Perf Quarter69.26%
Income-1030.50M P/S0.27 EPS this Y64.03% Inst Trans-15.82% Short Ratio5.12 Perf Half Y-46.33%
Sales2.73B P/B1.24 EPS next Y51.83% ROA-32.19% Short Interest12.94M Perf YTD-56.89%
Book/sh6.49 P/C8.99 EPS next 5Y47.01% ROE-100.49% 52W High25.28 -68.20% Perf Year-63.82%
Cash/sh0.89 P/FCF- EPS past 3/5Y- 3.94% ROIC-59.12% 52W Low3.97 102.52% Perf 3Y-
Dividend Est.- EV/EBITDA165.77 Sales past 3/5Y-4.10% 1.11% Gross Margin16.76% Volatility9.39% 11.64% Perf 5Y-
Dividend TTM- EV/Sales0.69 EPS Y/Y TTM-284.00% Oper. Margin-2.67% ATR (14)0.72 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.02 Sales Y/Y TTM-4.96% Profit Margin-37.70% RSI (14)67.66 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio1.02 EPS Q/Q-221.12% SMA2022.22% Beta1.87 Target Price6.90
Payout- Debt/Eq2.11 Sales Q/Q7.23% SMA5039.70% Rel Volume0.67 Prev Close7.90
Employees15500 LT Debt/Eq1.96 EarningsAug 06 BMO SMA200-29.08% Avg Volume2.53M Price8.04
IPOJun 16, 2023 Option/ShortYes / Yes EPS/Sales Surpr.150.99% 12.49% Trades Volume1,691,334 Change1.77%
Date Action Analyst Rating Change Price Target Change
Aug-04-25Upgrade Robert W. Baird Neutral → Outperform $9
May-02-25Initiated Truist Hold $7
Apr-10-25Downgrade Barclays Equal Weight → Underweight $6
Dec-11-24Downgrade Citigroup Buy → Neutral $30 → $23
Dec-06-24Downgrade Robert W. Baird Outperform → Neutral $28 → $25
Sep-25-24Downgrade Jefferies Buy → Hold $25 → $21
Aug-08-24Downgrade Evercore ISI Outperform → In-line $31 → $27
Jul-24-24Resumed Barclays Equal Weight $30
Jun-06-24Initiated Goldman Neutral $28
May-29-24Initiated TD Cowen Hold $27
Aug-13-25 01:37AM
Aug-12-25 08:00AM
03:18AM
Aug-07-25 08:48PM
Aug-06-25 01:20PM
07:45AM Loading…
07:45AM
07:36AM
06:30AM
Aug-05-25 06:00PM
08:15AM
Aug-04-25 11:06PM
04:30PM
Jul-29-25 08:00AM
07:20AM
Jul-23-25 03:36PM
02:05PM Loading…
Jul-22-25 02:05PM
08:45AM
Jul-18-25 08:45AM
Jul-16-25 07:00AM
Jul-15-25 08:58AM
08:00AM
Jul-11-25 12:51PM
10:46AM
09:00AM
Jul-07-25 08:06AM
Jun-30-25 08:55AM
08:00AM
Jun-26-25 09:49AM
Jun-24-25 09:15AM
07:00AM
11:40AM Loading…
Jun-20-25 11:40AM
Jun-16-25 11:38PM
Jun-13-25 12:15PM
Jun-12-25 08:36AM
Jun-11-25 04:10PM
Jun-04-25 09:35AM
Jun-03-25 04:05PM
May-30-25 12:00AM
May-13-25 03:05AM
May-12-25 06:03PM
07:50AM
06:40AM
06:30AM
May-09-25 12:37AM
May-08-25 06:00PM
May-07-25 10:00AM
May-05-25 10:00AM
09:46AM
May-01-25 07:00AM
12:32AM
Apr-15-25 07:00AM
Apr-13-25 10:44AM
Mar-31-25 08:05AM
Mar-25-25 09:00PM
Mar-20-25 08:07PM
Mar-18-25 05:04AM
Mar-04-25 02:02AM
01:04AM
Mar-03-25 06:45AM
Feb-21-25 03:33PM
Feb-20-25 07:00AM
Feb-06-25 07:17PM
Jan-30-25 07:00AM
Dec-07-24 05:15AM
Dec-05-24 04:05PM
Nov-26-24 04:15PM
04:15PM
Nov-12-24 06:45AM
Nov-11-24 12:31PM
Nov-09-24 02:04AM
Nov-08-24 10:15AM
06:30AM
Oct-17-24 07:00AM
Oct-14-24 07:00AM
Aug-13-24 12:58PM
Aug-12-24 07:04PM
07:00AM
Jul-17-24 07:00AM
Jul-11-24 08:42AM
08:00AM
Jun-27-24 07:00AM
Jun-19-24 05:02PM
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:01PM
07:00AM
May-21-24 09:48AM
May-17-24 10:15PM
May-16-24 04:05PM
May-15-24 03:56PM
May-14-24 06:43PM
03:01AM
May-13-24 06:50PM
10:52AM
06:30AM
May-06-24 08:22AM
Apr-30-24 01:58PM
Apr-11-24 07:00AM
Mar-12-24 11:24AM
Mar-11-24 06:30AM
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEUPERT PETER MDirectorAug 08 '25Buy6.7930,000203,70065,632Aug 11 08:21 PM
NEUPERT PETER MDirectorAug 11 '25Buy6.2632,500203,45098,132Aug 11 08:21 PM
Morais Mark A.Chief Operating OfficerJun 02 '25Option Exercise0.0011,007049,679Jun 04 05:44 PM
Morais Mark A.Chief Operating OfficerJun 03 '25Sale4.173,13013,05246,549Jun 04 05:44 PM
Mcconnell Jill G.Chief Financial OfficerJun 02 '25Option Exercise0.0011,007051,474Jun 04 05:43 PM
Mcconnell Jill G.Chief Financial OfficerJun 03 '25Sale4.173,13013,05248,344Jun 04 05:43 PM
Hanson James S.General CounselJun 02 '25Option Exercise0.007,706017,172Jun 04 05:42 PM
Hanson James S.General CounselJun 03 '25Sale4.172,1919,13614,981Jun 04 05:42 PM
Mcconnell Jill G.OfficerJun 03 '25Proposed Sale4.173,13013,050Jun 03 03:25 PM
Morais Mark A.OfficerJun 03 '25Proposed Sale4.173,13013,050Jun 03 03:23 PM
Hanson James S.OfficerJun 03 '25Proposed Sale4.172,1919,135Jun 03 03:15 PM
Smith David RossDirectorMay 14 '25Option Exercise0.007,282011,729May 16 04:51 PM
Pesicka Edward ADirectorMay 14 '25Option Exercise0.007,282013,636May 16 04:49 PM
Ray AmritDirectorMay 14 '25Option Exercise0.007,282013,636May 16 04:47 PM
SANDERS MACHELLEDirectorMay 14 '25Option Exercise0.007,28207,282May 16 04:45 PM
NEUPERT PETER MChief Executive OfficerMay 14 '25Option Exercise0.007,282035,632May 16 04:42 PM
Hanson James S.General CounselMar 13 '25Option Exercise0.002,998010,473Mar 17 04:37 PM
Hanson James S.General CounselMar 14 '25Sale9.701,0079,7689,466Mar 17 04:37 PM
Morais Mark A.Chief Operating OfficerMar 13 '25Option Exercise0.004,283039,879Mar 17 04:35 PM
Morais Mark A.Chief Operating OfficerMar 14 '25Sale9.701,20711,70838,672Mar 17 04:35 PM
Mcconnell Jill G.Chief Financial OfficerMar 13 '25Option Exercise0.004,283041,677Mar 17 04:33 PM
Mcconnell Jill G.Chief Financial OfficerMar 14 '25Sale9.701,21011,73740,467Mar 17 04:33 PM
Morais Mark A.Chief Operating OfficerMar 12 '25Option Exercise0.00725035,799Mar 14 04:32 PM
Morais Mark A.Chief Operating OfficerMar 13 '25Sale9.932032,01635,596Mar 14 04:32 PM
Mcconnell Jill G.Chief Financial OfficerMar 12 '25Option Exercise0.00935037,655Mar 14 04:31 PM
Mcconnell Jill G.Chief Financial OfficerMar 13 '25Sale9.932612,59237,394Mar 14 04:31 PM
Hanson James S.OfficerMar 14 '25Proposed Sale9.701,0079,766Mar 14 03:40 PM
Morais Mark A.OfficerMar 14 '25Proposed Sale9.701,20711,705Mar 14 03:40 PM
Mcconnell Jill G.OfficerMar 14 '25Proposed Sale9.701,21011,735Mar 14 03:40 PM
Morais Mark A.Chief Operating OfficerMar 11 '25Option Exercise0.001,573035,573Mar 13 04:54 PM
Morais Mark A.Chief Operating OfficerMar 12 '25Sale9.984994,98035,074Mar 13 04:54 PM
Mcconnell Jill G.Chief Financial OfficerMar 11 '25Option Exercise0.002,028037,363Mar 13 04:53 PM
Mcconnell Jill G.Chief Financial OfficerMar 12 '25Sale9.986436,41736,720Mar 13 04:53 PM
Morais Mark A.OfficerMar 13 '25Proposed Sale9.932032,015Mar 13 03:18 PM
Mcconnell Jill G.OfficerMar 13 '25Proposed Sale9.932612,591Mar 13 03:15 PM
Morais Mark A.OfficerMar 12 '25Proposed Sale9.984994,980Mar 12 03:15 PM
Mcconnell Jill G.OfficerMar 12 '25Proposed Sale9.986436,417Mar 12 03:09 PM
ECKERT R ANDREWDirectorFeb 21 '25Option Exercise0.007,282013,636Feb 25 05:12 PM
Morais Mark A.Chief Operating OfficerFeb 11 '25Option Exercise0.001,210034,424Feb 13 05:30 PM
Morais Mark A.Chief Operating OfficerFeb 12 '25Sale14.674246,22034,000Feb 13 05:30 PM
Mcconnell Jill G.Chief Financial OfficerFeb 11 '25Option Exercise0.001,544035,875Feb 13 05:28 PM
Mcconnell Jill G.Chief Financial OfficerFeb 12 '25Sale14.675407,92235,335Feb 13 05:28 PM
Mcconnell Jill G.OfficerFeb 12 '25Proposed Sale14.675407,923Feb 12 03:18 PM
Morais Mark A.OfficerFeb 12 '25Proposed Sale14.674246,221Feb 12 03:15 PM
Mcconnell Jill G.Chief Financial OfficerFeb 07 '25Option Exercise0.001,687034,909Feb 11 04:44 PM
Mcconnell Jill G.Chief Financial OfficerFeb 10 '25Sale14.805788,55434,331Feb 11 04:44 PM
Morais Mark A.Chief Operating OfficerFeb 07 '25Option Exercise0.002,256033,987Feb 11 04:42 PM
Morais Mark A.Chief Operating OfficerFeb 10 '25Sale14.8077311,44033,214Feb 11 04:42 PM
Morais Mark A.OfficerFeb 10 '25Proposed Sale14.8077311,440Feb 10 04:22 PM
Mcconnell Jill G.OfficerFeb 10 '25Proposed Sale14.805788,554Feb 10 04:07 PM
Pike ThomasChief Executive OfficerJan 10 '25Option Exercise0.0040,2200171,136Jan 14 06:08 PM
Pike ThomasChief Executive OfficerJan 13 '25Sale18.0411,268203,275159,868Jan 14 06:08 PM
Pike ThomasOfficerJan 13 '25Proposed Sale18.0411,268203,288Jan 13 03:12 PM
Morais Mark A.Chief Operating OfficerDec 15 '24Option Exercise0.00406031,910Dec 17 05:18 PM
Morais Mark A.Chief Operating OfficerAug 19 '24Option Exercise0.0011,312036,464Aug 20 05:37 PM
Mcconnell Jill G.Chief Financial OfficerAug 19 '24Option Exercise0.0011,312038,194Aug 20 05:36 PM
Pike ThomasChief Executive OfficerAug 19 '24Option Exercise0.00125,6910183,518Aug 20 05:34 PM
Last Close
Aug 15 04:00PM ET
13.04
Dollar change
+0.12
Percentage change
0.93
%
ADPT Adaptive Biotechnologies Corp daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.81 Insider Own4.61% Shs Outstand152.23M Perf Week6.89%
Market Cap1.99B Forward P/E- EPS next Y-0.59 Insider Trans-16.83% Shs Float145.25M Perf Month24.19%
Enterprise Value2.01B PEG- EPS next Q-0.20 Inst Own95.03% Short Float6.84% Perf Quarter46.35%
Income-121.23M P/S9.68 EPS this Y29.50% Inst Trans3.59% Short Ratio5.17 Perf Half Y53.05%
Sales205.22M P/B11.05 EPS next Y22.70% ROA-22.42% Short Interest9.93M Perf YTD117.51%
Book/sh1.18 P/C10.04 EPS next 5Y32.24% ROE-57.55% 52W High13.37 -2.47% Perf Year185.96%
Cash/sh1.30 P/FCF- EPS past 3/5Y9.79% -1.51% ROIC-31.52% 52W Low3.98 227.56% Perf 3Y3.33%
Dividend Est.- EV/EBITDA- Sales past 3/5Y5.06% 16.04% Gross Margin60.69% Volatility5.13% 6.39% Perf 5Y-65.32%
Dividend TTM- EV/Sales9.77 EPS Y/Y TTM44.48% Oper. Margin-58.88% ATR (14)0.71 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.75 Sales Y/Y TTM21.60% Profit Margin-59.07% RSI (14)70.74 Recom1.29
Dividend Gr. 3/5Y- - Current Ratio2.84 EPS Q/Q46.30% SMA2014.74% Beta1.94 Target Price14.00
Payout- Debt/Eq1.21 Sales Q/Q36.33% SMA5016.91% Rel Volume0.98 Prev Close12.92
Employees619 LT Debt/Eq1.14 EarningsAug 05 AMC SMA20057.17% Avg Volume1.92M Price13.04
IPOJun 27, 2019 Option/ShortYes / Yes EPS/Sales Surpr.28.81% 19.20% Trades Volume1,877,220 Change0.93%
Date Action Analyst Rating Change Price Target Change
Jun-18-25Initiated Craig Hallum Buy $15
Mar-21-25Upgrade Goldman Neutral → Buy $9
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Aug-13-25 09:15AM
Aug-08-25 09:40AM
Aug-06-25 07:01PM
03:30AM
Aug-05-25 07:30PM
06:00PM Loading…
06:00PM
04:57PM
04:05PM
Aug-04-25 09:38AM
Aug-01-25 08:10AM
Jul-22-25 08:14AM
Jul-15-25 04:05PM
Jul-04-25 09:40AM
Jul-01-25 07:30AM
Jun-26-25 09:49AM
01:01PM Loading…
Jun-25-25 01:01PM
Jun-13-25 12:00PM
Jun-11-25 09:40AM
Jun-03-25 04:05PM
May-30-25 07:30AM
May-29-25 11:18AM
11:08AM
06:20AM
May-28-25 04:05PM
May-26-25 09:40AM
May-20-25 06:20AM
May-19-25 09:06AM
May-15-25 08:42AM
May-14-25 06:29AM
May-09-25 12:41PM
12:00PM Loading…
12:00PM
08:55AM
08:06AM
May-08-25 09:55AM
09:40AM
May-02-25 09:29AM
03:18AM
May-01-25 09:46PM
07:00PM
05:35PM
04:30PM
04:05PM
Apr-24-25 09:45AM
Apr-14-25 02:09PM
Apr-12-25 09:15AM
Apr-10-25 04:05PM
Apr-08-25 08:00AM
Mar-20-25 03:06PM
Mar-11-25 08:00AM
Feb-14-25 10:44AM
Feb-12-25 12:00PM
09:56AM
09:40AM
02:11AM
Feb-11-25 06:30PM
05:35PM
04:45PM
04:05PM
Feb-10-25 07:19AM
Feb-05-25 04:05PM
Feb-04-25 10:28AM
Jan-23-25 05:06PM
06:21AM
Jan-22-25 04:05PM
Jan-17-25 09:40AM
Jan-16-25 08:33AM
Jan-15-25 10:10AM
Jan-14-25 07:30AM
Jan-07-25 07:30AM
Jan-02-25 04:05PM
Dec-09-24 09:53AM
Dec-07-24 06:30PM
Dec-05-24 07:16AM
Dec-03-24 07:30AM
Nov-29-24 09:40AM
Nov-25-24 01:55PM
Nov-15-24 09:55AM
Nov-08-24 10:18AM
02:29AM
Nov-07-24 06:30PM
06:15PM
05:11PM
04:05PM
07:30AM
Nov-06-24 07:28AM
Oct-09-24 04:05PM
Oct-04-24 04:35AM
Aug-29-24 07:30AM
Aug-22-24 04:03PM
Aug-01-24 07:00PM
06:20PM
05:23PM
04:05PM
Jul-21-24 06:00AM
Jul-15-24 12:00PM
Jul-11-24 04:05PM
May-31-24 07:30AM
May-29-24 04:05PM
May-25-24 08:30AM
May-24-24 09:58AM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PISKEL KYLEChief Financial OfficerMay 16 '25Sale8.891,92917,149277,396May 19 07:59 PM
ROBINS HARLAN SChief Scientific OfficerMay 01 '25Option Exercise6.3268,412432,3641,347,936May 05 05:27 PM
ROBINS HARLAN SChief Scientific OfficerMay 01 '25Sale7.3568,412502,8281,279,524May 05 05:27 PM
Harlan RobinsOfficerMay 01 '25Proposed Sale7.3668,412503,512May 01 05:38 PM
ROBINS HARLAN SChief Scientific OfficerMar 24 '25Option Exercise6.321,69810,7311,281,222Mar 26 06:48 PM
ROBINS HARLAN SChief Scientific OfficerMar 24 '25Sale9.001,69815,2821,279,524Mar 26 06:48 PM
Harlan RobinsOfficerMar 24 '25Proposed Sale8.661,69814,705Mar 24 05:45 PM
PISKEL KYLEChief Financial OfficerMar 14 '25Option Exercise6.322,50015,800271,510Mar 17 07:34 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Sale7.1936,291260,93215,394Mar 17 07:33 PM
GRIFFIN MICHELLE RENEEDirectorMar 13 '25Proposed Sale7.1936,291260,861Mar 13 05:28 PM
HERSHBERG ROBERTDirectorMar 12 '25Sale7.5953,000402,27069,690Mar 12 07:48 PM
NEUPERT PETER MDirectorMar 10 '25Option Exercise4.0750,000203,500234,690Mar 12 07:47 PM
NEUPERT PETER MDirectorMar 10 '25Sale7.0510,00070,500224,690Mar 12 07:47 PM
HERSHBERG ROBERTDirectorMar 12 '25Proposed Sale7.5953,000402,270Mar 12 05:30 PM
NEUPERT PETER MDirectorMar 10 '25Proposed Sale7.0510,00070,450Mar 10 02:48 PM
LO FRANCISChief People OfficerMar 05 '25Sale6.9920,875145,845332,846Mar 06 07:22 PM
BOBULSKY SUSANChief Commercial Officer, MRDMar 05 '25Sale6.9826,023181,641347,238Mar 06 07:22 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 05 '25Sale6.9844,665311,792392,723Mar 06 07:21 PM
PISKEL KYLEChief Financial OfficerMar 05 '25Sale6.9810,32072,072269,010Mar 06 07:20 PM
RUBINSTEIN JULIEPresident and COOMar 05 '25Sale6.9859,505415,540588,249Mar 06 07:19 PM
ROBINS HARLAN SChief Scientific OfficerMar 05 '25Sale6.9996,656675,2191,279,524Mar 06 07:18 PM
ROBINS CHAD MCEO and ChairmanMar 05 '25Sale6.98117,351819,4712,814,350Mar 06 07:17 PM
ROBINS CHAD MCEO and ChairmanMar 06 '25Sale7.64102,218780,9462,959,249Mar 06 07:17 PM
GRIFFIN MICHELLE RENEEDirectorMar 06 '25Sale7.9415,664124,37251,685Mar 06 07:14 PM
MICHELLE GRIFFINDirectorMar 06 '25Proposed Sale7.9415,664124,440Mar 06 04:10 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Option Exercise6.32186,0801,176,0262,762,781Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Option Exercise6.3299,107626,3562,675,808Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 19 '25Sale8.46186,0801,574,2372,576,701Feb 21 07:28 PM
ROBINS CHAD MCEO and ChairmanFeb 20 '25Sale8.4499,107836,4632,576,701Feb 21 07:28 PM
Chad RobinsOfficerFeb 20 '25Proposed Sale8.3799,107829,526Feb 20 04:02 PM
Chad RobinsOfficerFeb 19 '25Proposed Sale8.37186,0801,557,490Feb 19 04:51 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Option Exercise6.32211,1601,334,5312,787,861Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Option Exercise6.32158,9211,004,3812,735,622Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Option Exercise6.32100,287633,8142,676,988Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 18 '25Sale8.50211,1601,794,8602,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 14 '25Sale8.46158,9211,344,4722,576,701Feb 18 08:21 PM
ROBINS CHAD MCEO and ChairmanFeb 13 '25Sale8.44100,287846,4222,576,701Feb 18 08:21 PM
Chad RobinsOfficerFeb 18 '25Proposed Sale8.27211,1601,746,293Feb 18 05:35 PM
Chad RobinsOfficerFeb 14 '25Proposed Sale8.33158,9211,323,812Feb 14 04:11 PM
Chad RobinsOfficerFeb 13 '25Proposed Sale8.52100,287854,445Feb 13 05:11 PM
PISKEL KYLEChief Financial OfficerNov 18 '24Sale4.982481,235154,330Nov 19 06:45 PM
BOBULSKY SUSANChief Commercial Officer, MRDOct 08 '24Option Exercise1.985,0009,900253,290Oct 10 05:47 PM
Taylor Stacy LSVP and General CounselAug 22 '24Sale4.5026,922121,079139,365Aug 23 04:27 PM
STACY L TAYLOROfficerAug 22 '24Proposed Sale4.5026,922121,079Aug 22 04:18 PM